Hemogenyx Pharmaceuticals PLC Hemogenyx scientific advisor receives Lasker Award

TIDMHEMO

Hemogenyx Pharmaceuticals PLC

12 September 2019

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Hemogenyx scientific advisor receives Lasker Award

H. Michael Shepard becomes second board member to win prestigious prize for medical research

Brooklyn, N.Y. - Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that H. Michael Shepard, a member of Henogenyx's Scientific Advisory Board, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award. The award is given annually for biological discoveries and clinical advances that improve human health. The Lasker Awards are America's most prestigious medical research awards, the US "Nobel". This year's prize recognizes Dr. Shepard's pivotal role in the invention of Herceptin, a life-saving therapy for women with breast cancer. Herceptin is credited with reducing the risk of breast cancer recurrence and extending the survival time for patients with metastatic as well as early-stage disease.

In awarding the prize to Dr. Shepard, the Lasker Foundation said that Shepard's research "executed a new blueprint for drug discovery that has already bestowed tens of thousands of women with time and quality of life."

Upon learning of the honor, Dr. Vladislav Sandler, Hemogenyx's Chief Executive Officer, commented, "We are thrilled that Dr. Shepard's life-saving work has been recognized by this prestigious award and we are fortunate to have such a distinguished scientist advising our own organization's cutting-edge cancer research."

Shepard becomes the second Hemogenyx board member to win the prestigious prize. In 2003, Chairman of the Board Sir Marc Feldmann received the Lasker Award for his ground-breaking discovery of antibodies that block TNF, an effective treatment for rheumatoid arthritis and other autoimmune diseases.

"Michael Shepard is a pioneering scientist whose research has improved millions of lives," said Sir Marc. "I'm an admirer of his achievements and proud to be his friend and have introduced him to Hemogenyx, where his expertise will help us achieve our goals."

For further information on the award, please follow this link:

http://www.laskerfoundation.org/awards/show/herceptin-targeted-antibody-therapy-breast-cancer/

Enquiries:

 
 Hemogenyx Pharmaceuticals plc              www.hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive      [e-mail] 
  Officer & Co-Founder 
 Sir Marc Feldmann, Chairman 
 
 SP Angel Corporate Finance LLP             Tel: [phone] 
                                             0470 
 Matthew Johnson, Vadim Alexandre, Soltan 
  Tagiev 
 
 Peterhouse Corporate Finance Limited       Tel: [phone] 
                                             0930 
 Lucy Williams, Duncan Vasey 
 
 US Media enquiries                         Tel: [phone] 
 Lowell Goodman                             [e-mail] 
 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRALBMITMBMBBFL

(END) Dow Jones Newswires

September 12, 2019 02:01 ET (06:01 GMT)